Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M S
Tumor Immunology and Biotherapy Center, Eastern Institute of Hepatobiliary Surgery, Shanghai, China.
Science. 1994 Jan 28;263(5146):518-20. doi: 10.1126/science.7507262.
Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH-2-B hybrid cells became resistant to challenge with parental BERH-2 cells, and rats with established BERH-2 hepatomas were cured by subsequent injection of BERH-2-B cells. Both CD4+ and CD8+ cells were essential for the induction of protective immunity; however, only CD8+ cells were required for the eradication of BERH-2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.
BERH-2大鼠肝癌细胞与活化的B细胞融合产生了失去致瘤性并具有免疫原性的杂交细胞。注射了BERH-2-B杂交细胞的同基因大鼠对亲代BERH-2细胞的攻击产生了抗性，而患有已确立的BERH-2肝癌的大鼠通过随后注射BERH-2-B细胞而被治愈。CD4+和CD8+细胞对于诱导保护性免疫都是必不可少的；然而，根除BERH-2肿瘤仅需要CD8+细胞。产生引发抗肿瘤免疫反应的杂交肿瘤细胞可能是癌症免疫治疗的一种有用策略。
